The coordinated C-suite sale at identical price and date is characteristic of a pre-planned 10b5-1 trading plan or post-blackout window execution, not a bearish signal. Monitor for any 8-K filing or press release in the next 10 days that could explain the timing, but the dollar amount is too small to move the stock. The 30-day prior insider activity (5 sells, $1.1M) shows this is part of a routine pattern.
PGEN drugs
PGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $3.86entry
- T+1 · 6mo ago −1.30%α −0.60% · $3.81
- T+5 · 5mo ago −3.89%α −0.92% · $3.71
- T+20 · 5mo ago +36.01%α +37.58% · $5.25
- T+60 · 3mo ago +92.23%α +91.11% · $7.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four top executives at Precigen (CEO, CFO, COO, CLO) sold a combined $1.02M in open-market sales on May 28, 2026, all at $4.36/share. This is a coordinated cluster sale by the entire C-suite, representing 0.07% of the $1.5B market cap, a trivial proportion. The simultaneous timing and identical price suggest a pre-arranged 10b5-1 plan or blackout-window opening, not a reaction to imminent news.
Key Financial Metrics
Key Facts
- Four C-suite insiders sold on the same day (May 28, 2026) at the same price ($4.36).
- Total open-market sales: $1.02M across 263,240 shares.
- Sales represent only 0.07% of Precigen's $1.5B market cap.
- CEO Helen Sabzevari sold the largest portion: $520K (119,250 shares).
- No insider purchases were filed in the same window.
Financial Impact
Total insider sales of $1.02M, or 0.07% of market cap, immaterial relative to company size.
Risk Factors
- If the sales were NOT under a 10b5-1 plan, the unanimity of C-suite selling could signal a shared bearish view on upcoming data or earnings.
- Precigen is a clinical-stage biotech with binary pipeline catalysts, insider selling ahead of a data readout would be a red flag.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PGEN-1780345870355 |
Track record
13 reports on PGEN
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Viewing Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers